




+


Healthcare Headline Transactions


	Target	Acquiror	Acquisition Synopsis
Biotechnology / Pharmaceuticals	<i>C</i> Shire	abbvie	 AbbVie Inc. (NYSE:ABBV) offered to acquire Shire plc (LSE:SHP) for \$53.7 billion in cash and stock after three previous offers which were declined by Shire. AbbVie Inc., a research-based biopharmaceutical company, develops a range of therapies around chronic autoimmune diseases. Shire plc develops specialty medicine products in the areas of rare diseases, neuroscience, gastrointestinal and internal medicine. Implied Enterprise Value Multiples: 10.2x Revenues, 23.9x EBITDA
Medical Devices		A Medtronic	 Medtronic, Inc. (NYSE:MDT) announced its proposed acquisition of Covidien plc (NYSE:COV) for \$42.9 billion in cash and stock. Medtronic manufactures device-based medical therapies, which treat many conditions, including cardiac & vascular diseases, diabetes and neurological & spinal conditions. Covidien develops and manufactures healthcare products for clinical and home settings including endomechanical instruments and soft tissue repair products. Implied Enterprise Value Multiples: 4.5x Revenues, 16.8x EBITDA
Biotechnology / Pharmaceuticals	IDENIX	Sector Merck	 Merck & Co. Inc. (NYSE:MRK) agreed to acquire Idenix Pharmaceuticals Inc. (NasdaqGS:IDIX) for \$3.9 billion. Merck & Co. Inc. provides health solutions through its prescription medicines, vaccines, biologic therapies, animal health and consumer care products. Idenix, a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France.
Biotechnology / Pharmaceuticals	L A B R Y S BIOLOGICS	ᡪᢧᡜ᠇ᡔ᠋	 Teva Pharmaceutical Industries Limited (NYSE:TEVA) agreed to acquire Labrys Biologics, Inc. for \$200 million in cash at closing as well as up to \$625 million in contingent payments upon achievement of certain milestones. Teva develops, manufactures, sells and distributes generic and proprietary pharmaceuticals and active pharmaceutical ingredients worldwide. Labrys Biologics, Inc., a development stage company, operates as a biotechnology firm and develops antibody treatments for chronic migraines.


Enterprise Value / LTM Revenue












Enterprise Value / LTM EBITDA

Note: EBITDA Margins in red

LTM Stock Price Index



Jan-14

Jul-13 Aug-13

Feb-14 Mar-14 Apr-14 May-14 Jun-14 Jul-14

Selected Biotechnology / Pharma Transactions

Sep-13 Oct-13 Nov-13 Dec-13

Target	Acquiror	Target Description
DAVA	Generics	DAVA Pharmaceuticals, Inc. develops and
Pharmaceuticals, Inc.	Inc.	markets generic pharmaceutical products in the form of tablets and capsules. Deal Value: \$600 million
OSO BioPharmaceuticals Manufacturing, LLC	Albany Molecular Research Inc.	OSO BioPharmaceuticals manufactures injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products. Deal Value: \$110 million
E. Claiborne Robins Valeant Company, Inc. Pharmaceutica International, In		E. Claiborne Robins Company, Inc. (dba ECR), manufactures pharmaceutical products related to allergies and cough & cold. Deal Value: \$41 million

Selected Life Sciences / Diagnostics Transactions

Target	Acquiror	Target Description
ProteinSimple	Techne Corp.	ProteinSimple develops and commercializes proprietary systems and consumables for protein analysis. Deal Value: \$312 million
Refine Technology, LLC	Repligen Corporation	Refine Technology develops equipment for the enhancement of cell culture processes in biopharmaceutical industry. Deal Value: \$33 million
RadCore Lab, LLC	Cardiocore Lab, Inc.	RadCore Lab, LLC offers imaging endpoint solutions for pharmaceutical, biotechnology and medical device clinical trials.

Recent TM & Asante Transactions



Selected Healthcare Services Transactions

Target	Acquiror	Target Description
Evolution1, Inc.	WEX Inc.	Evolution1, Inc. provides electronic payment, on-premise and cloud computing healthcare solutions. Deal Value: \$533 million
Capario, Inc.	Emdeon Inc.	Capario, Inc. provides revenue cycle management solutions that connect healthcare providers and payers. Deal Value: \$115 million
SimBioSys Inc.	John Wiley & Sons Inc.	SimBioSys designs and develops 3D molecular modeling software solutions for the pharmaceutical drug discovery industry.

Selected Medical Device Transactions

Target Acquiror		Target Description
Ulthera, Inc.	Merz North America, Inc.	Ulthera, Inc. focuses on the development of various technologies for aesthetic and medical applications. Deal Value: \$600 million
Small Bone Innovations, Inc.	Stryker Corporation	Small Bone manufactures and supplies orthopedics devices and instruments to treat trauma and diseases in small bones and joints. Deal Value: \$375 million
Medical Action Owens & Minor Industries Inc. Inc.		Medical Action Industries Inc. develops and supplies disposable medical products and sterilization products. Deal Value: \$287 million

TM Asante Healthcare Partners Contacts



Managing Director

jmclaren@tmcapital.com

212-809-1414







Paul R. Smolevitz Managing Director psmolevitz@tmcapital.com 212-809-1416

TM Asante Healthcare Partners is a dedicated industry-focused investment banking practice that combines TM Capital's extensive healthcare industry experience with the healthcare investment banking credentials of James McLaren, the co-founder of Asante Partners. TM Capital, a partner-owned investment banking firm based in New York, Boston and Atlanta, has built strong industry expertise over 25 years of completing healthcare M&A and financing transactions. Asante Partners and its predecessor firm have more than two decades of industry knowledge and relationships as a boutique investment bank focused exclusively on healthcare. Together, TM and Asante have completed over 75 healthcare mergers, acquisitions and financings valued at over \$3 billion. For more information, visit www.tmcapital.com/tm-asante.

New York 641 Lexington Avenue 30th Floor New York, NY 10022 Tel: 212.809.1360 **Boston** 200 Clarendon Street 25th Floor Boston, MA 02116 Tel: 617.259.2200

Atlanta 15 Piedmont Center NE Suite 1010 Atlanta, GA 30305 Tel: 404.995.6230

